Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Northwest Biotherapeutics (NWBO) Revenue (2016 - 2025)

Northwest Biotherapeutics (NWBO) has 16 years of Revenue data on record, last reported at $200000.0 in Q3 2025.

  • For Q3 2025, Revenue fell 43.98% year-over-year to $200000.0; the TTM value through Sep 2025 reached $937000.0, down 41.29%, while the annual FY2024 figure was $1.4 million, 28.47% down from the prior year.
  • Revenue reached $200000.0 in Q3 2025 per NWBO's latest filing, up from $131000.0 in the prior quarter.
  • Across five years, Revenue topped out at $880000.0 in Q1 2023 and bottomed at $131000.0 in Q2 2025.
  • Average Revenue over 5 years is $372666.7, with a median of $366000.0 recorded in 2024.
  • Peak YoY movement for Revenue: surged 20700.0% in 2021, then plummeted 74.31% in 2025.
  • A 5-year view of Revenue shows it stood at $350000.0 in 2021, then skyrocketed by 70.57% to $597000.0 in 2022, then fell by 25.46% to $445000.0 in 2023, then crashed by 48.09% to $231000.0 in 2024, then dropped by 13.42% to $200000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Revenue were $200000.0 in Q3 2025, $131000.0 in Q2 2025, and $375000.0 in Q1 2025.